Quick Answer
Whitehawk Therapeutics, Inc. reported Net Income Loss of -$20.60 million for the year ending 2025.
- Whitehawk Therapeutics, Inc. showed an increase of +67.7% in Net Income Loss from 2024 to 2025.
- This data is from Whitehawk Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2007 to 2025 (19 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 19 years of available data (2007 to 2025), Whitehawk Therapeutics, Inc.'s Net Income Loss has declined by 137,417.5%.
- Historical annual values: Fiscal year 2025: -$20.60 million | Fiscal year 2024: -$63.69 million | Fiscal year 2023: -$65.77 million | Fiscal year 2022: -$60.51 million | Fiscal year 2021: -$110.09 million | Fiscal year 2020: -$3.48 million | Fiscal year 2019: -$23.27 million | Fiscal year 2018: -$10.40 million | Fiscal year 2017: -$21.40 million | Fiscal year 2016: -$16.98 million | Fiscal year 2015: -$31.4 thousand | Fiscal year 2014: -$30.8 thousand | Fiscal year 2013: -$28.7 thousand | Fiscal year 2012: -$27.4 thousand | Fiscal year 2011: -$27.2 thousand | Fiscal year 2010: -$22.4 thousand | Fiscal year 2009: -$20.0 thousand | Fiscal year 2008: -$33.6 thousand | Fiscal year 2007: -$15.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: